Since joining HGF in 2014, Fiona has worked on drafting and prosecuting patent applications in a range of practice areas in the chemical field including pharmaceuticals, physical chemistry and nanomaterials.
Prior to joining HGF, Fiona obtained a First Class MSci in Forensic and Analytical Chemistry from the University of Strathclyde in 2009, during which she undertook a one-year industrial placement at Pfizer.
Fiona then moved to Cambridge University to accept a place on the Nanoscience and Technology Doctoral Training Centre. Fiona's doctoral research involved investigating routes to understanding the aggregation behaviour of insulin through the use of supramolecular chemistry. Following the submission of her thesis, Fiona completed a short research internship at the Ecole Normale Superieure in Paris, France working towards the manipulation of particle deposition in evaporating droplets.
Fiona qualified as a Chartered Patent Attorney and as a European Patent Attorney in 2019.
Forensic and Analytical Chemistry, University of Strathclyde, 2009
Chemistry, University of Cambridge, 2014
PGCert IP, University of Bournemouth
Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …Read article
Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder . …Read article
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …Event details
HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.